281 related articles for article (PubMed ID: 25102089)
1. Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood.
Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
AIDS; 2014 Nov; 28(17):2625-7. PubMed ID: 25102089
[TBL] [Abstract][Full Text] [Related]
2. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):107-14. PubMed ID: 25402233
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.
Kraft JC; McConnachie LA; Koehn J; Kinman L; Sun J; Collier AC; Collins C; Shen DD; Ho RJY
J Control Release; 2018 Apr; 275():229-241. PubMed ID: 29432823
[TBL] [Abstract][Full Text] [Related]
4. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
McConnachie LA; Kinman LM; Koehn J; Kraft JC; Lane S; Lee W; Collier AC; Ho RJY
J Pharm Sci; 2018 Jul; 107(7):1787-1790. PubMed ID: 29548975
[TBL] [Abstract][Full Text] [Related]
5. Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates.
Koehn J; Iwamoto JF; Kraft JC; McConnachie LA; Collier AC; Ho RJY
AIDS; 2018 Nov; 32(17):2463-2467. PubMed ID: 30102655
[TBL] [Abstract][Full Text] [Related]
6. Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs Lopinavir, Ritonavir, and Tenofovir in plasma.
Koehn J; Ho RJ
Antimicrob Agents Chemother; 2014 May; 58(5):2675-80. PubMed ID: 24566184
[TBL] [Abstract][Full Text] [Related]
7. Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
Perazzolo S; Shireman LM; Koehn J; McConnachie LA; Kraft JC; Shen DD; Ho RJY
J Pharm Sci; 2018 Dec; 107(12):3153-3162. PubMed ID: 30121315
[TBL] [Abstract][Full Text] [Related]
8. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.
Kraft JC; McConnachie LA; Koehn J; Kinman L; Collins C; Shen DD; Collier AC; Ho RJ
AIDS; 2017 Mar; 31(6):765-770. PubMed ID: 28099191
[TBL] [Abstract][Full Text] [Related]
9. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based Pharmacokinetic Model Validated to Enable Predictions Of Multiple Drugs in a Long-acting Drug-combination Nano-Particles (DcNP): Confirmation with 3 HIV Drugs, Lopinavir, Ritonavir, and Tenofovir in DcNP Products.
Perazzolo S; Shen DD; Scott AM; Ho RJY
J Pharm Sci; 2024 Jun; 113(6):1653-1663. PubMed ID: 38382809
[TBL] [Abstract][Full Text] [Related]
11. Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Wang X; Boffito M; Zhang J; Chung E; Zhu L; Wu Y; Patterson K; Kashuba A; Tebas P; Child M; Mahnke L; Bertz R
AIDS Patient Care STDS; 2011 Sep; 25(9):509-15. PubMed ID: 21770762
[TBL] [Abstract][Full Text] [Related]
12. No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla.
Burger D; van Luin M; Bosch M; van der Ven A; Brouwer AM; Keuter M; Dofferhoff T; Koopmans PP
J Acquir Immune Defic Syndr; 2010 Aug; 54(5):e12-3. PubMed ID: 20647821
[No Abstract] [Full Text] [Related]
13. Antiretroviral nanoparticles: the future is now.
Martínez E; Blanco JL
AIDS; 2014 Nov; 28(17):2623-4. PubMed ID: 25574963
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles.
Duan J; Freeling JP; Koehn J; Shu C; Ho RJ
J Pharm Sci; 2014 Aug; 103(8):2520-9. PubMed ID: 24948204
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral nanoparticles: the future is now: authors' response to editorial comments.
Freeling JP; Ho RJ
AIDS; 2015 Apr; 29(7):863-4. PubMed ID: 25985411
[No Abstract] [Full Text] [Related]
17. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
[TBL] [Abstract][Full Text] [Related]
18. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
[TBL] [Abstract][Full Text] [Related]
19. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
Bartlett JA; Ribaudo HJ; Wallis CL; Aga E; Katzenstein DA; Stevens WS; Norton MR; Klingman KL; Hosseinipour MC; Crump JA; Supparatpinyo K; Badal-Faesen S; Kallungal BA; Kumarasamy N
AIDS; 2012 Jul; 26(11):1345-54. PubMed ID: 22441252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
